Quantitation of myocardial fatty acid metabolism using PET

Journal of Nuclear Medicine

Volumn 37, Issue 10, 1996, Pages 1723-1730

  Bergmann, Steven R ^a,b   Weinheimer, Carla J ^a   Markham, Joanne ^a   Herrero, Pilar ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Columbia University ^*  (United States)

Author keywords

mathematical models; oxidation; palmitate; tracers

Indexed keywords

OXFENICINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DIAGNOSTIC IMAGING; DOG; FATTY ACID METABOLISM; FATTY ACID OXIDATION; HEART ARRHYTHMIA; HEART MUSCLE METABOLISM; MATHEMATICAL MODEL; NONHUMAN; OXYGEN CONSUMPTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE DIAGNOSIS;

ANIMALS; BLOOD PRESSURE; CARBON RADIOISOTOPES; CORONARY CIRCULATION; DOBUTAMINE; DOGS; FATTY ACIDS; GLUCOSE; GLYCINE; HEART; LACTIC ACID; MYOCARDIUM; OXYGEN CONSUMPTION; PALMITATES; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0029840737     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (37)

1. Bing RJ. Cardiac metabolism. Physiol Rev 1965;45:171-213.
2. Lietdke AJ. Alterations of carbohydrate and lipid metabolism in the acutely ischemic heart. Prog Cardiovasc Dis 1981;23:321-336.
3. Neely JR, Morgan HE. Relationship between carbohydrate and lipid metabolism and the energy balance of heart muscle. Ann Rev Physiol 1974;36:413-459.
4. Camici P, Ferrannini E, Opie LH. Myocardial metabolism in ischemic heart disease: basic principles and application to imaging by positron emission tomography. Prog Cardiovasc Dis 1989;32:217-238.
5. Hale DE, Bennett MJ. Fatty acid oxidation disorders: a new class of metabolic diseases. J Pediatr 1992;121:1-11.
6. Paulson DJ, Noonan JJ, Ward KM, et al. Effects of POCA on metabolism and function in the ischemic rat heart. Basic Res Cardiol 1986;81:180-187.
7. Corr PB, Creer MH, Yamada KA, et al. Prophylaxis of early ventricular fibrillation by inhibition of acylcarnitine accumulation. J Clin Invest 1989;83:927-936.
8. Myears DW, Sobel BE, Bergmann SR. Substrate use in ischemic and reperfused canine myocardium: quantitative considerations. Am J Physiol:Heart Circ Physiol 1987;253: H107-H114.
9. Trauner DA, Horvath E, Davis LE. Inhibition of fatty acid beta-oxidation by influenza B virus and salicylic acid in mice: implications for Reye's syndrome. Neurology 1988;38:239-241.
10. Deschamps D, Fisch C, Fromenty B, et al. Inhibition by salicylic acid of the activation and thus oxidation of long-chain fatty acids. Possible role in the development of Reye's syndrome. J Pharmacol Exp Ther 1991;259:894-904.
11. Lerch RA, Bergmann SR, Sobel BE. Delineation of myocardial fatty acid metabolism with positron emission tomography. In: Bergmann SR, Sobel BE, eds. Positron emission tomography of the heart. Mount Kisco, NY: Futura Publishing, Inc.; 1992: 129-152.
12. Goldstein RA, Klein MS, Welch MJ, Sobel BE. External assessment of myocardial metabolism with Carbon-11-palmitate in vivo. J Nucl Med 1980;21:342-348.
13. Schön HR, Schelbert HR, Robison C, et al. Carbon-11-labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. I. Kinetics of Carbon-11-palmitic acid in normal myocardium. Am Heart J 1982;103:532-547.
14. Schön HR, Schelbert HR, Najafi A, et al. Carbon-11-labeled palmitic acid for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. II. Kinetics of Carbon-11-palmitic acid in acutely ischemic myocardium. Am Heart J 1982;103:548-561.
15. Schelbert HR, Henze E, Keen R, et al. Carbon-11-palmitate for the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. IV. In vivo evaluation of acute demand-induced ischemia in dogs. Am Heart J 1983;106:736-750.
16. 11C-labeled palmitate. Circulation 1980;61:242-255.
17. 11C-palmitate Circulation 1977;55:853-857.
18. Bergmann SR, Fox KAA, Ter-Pogossian MM, et al. Clot-selective coronary thrombolysis with tissue-type plasminogen activator. Science 1983;220:1181-1183.
19. Knabb RM, Rosamond TL, Fox KAA, et al. Enhancement of salvage of reperfused ischemic myocardium by diltiazem. J Am Coll Cardiol 1986;8:861-871.
20. Sobel BE, Geltman EM, Tiefenbrunn AJ, et al. Improvement of regional myocardial metabolism after coronary thrombolysis induced with tissue-type plasminogen activator or streptokinase. Circulation 1984;69:983-990.
21. Fox KAA, Abendschein D, Ambos HD, et al. Efflux of metabolized and nonmetabolized fatty acid from canine myocardium. Implications for quantifying myocardial metabolism tomographically. Circ Res 1985;57:232-243.
22. Rosamond TL, Abendschein DR, Sobel BE, et al. Metabolic fate of radiolabeled palmitate in ischemic canine myocardium: implications for positron-emission tomography. J Nucl Med 1987;28:1322-1329.
23. Schelbert HR, Henze E, Schön HR, et al. Carbon-11-palmitate foi the noninvasive evaluation of regional myocardial fatty acid metabolism with positron-computed tomography. III. In vivo demonstration of the effects of substrate availability on myocardial metabolism. Am Heart J 1983;105:492-504.
24. Schelbert HR, Henze E, Sochor H, et al. Effects of substrate availability on myocardial Carbon-11-palmitate kinetics by positron-emission tomography in normal subjects and patients with ventricular dysfunction. Am Heart J 1986;111:1055-1064.
25. Kelly DP, Mendelsohn NJ, Sobel BE, Bergmann SR. Detection of impaired myocardial fatty acid utilization by positron-emission tomography indicative of genetic deficiency of long-chain acyl-CoA dehydrogenase. Am J Cardiol 1993;71:738-744.
26. Sochor H, Schelbert HR, Schwaiger M, et al. Studies of fatty acid metabolism with positron-emission tomography in patients with cardiomyopathy. Eur J Nucl Med 1986;12:S66-S69.
27. Bergmann SR, Rubin, PR, Hartman JJ, Herrero P. Detection of abnormalities in fatty acid metabolism in patients with cardiomyopathy using PET [Abstract]. J Nucl Med 1995;36:142P.
28. Higgins AJ, Morville M, Burges RA, Blackburn KJ. Mechanism of action of oxfenicine on muscle metabolism. Biochem Biophys Res Comm 1981;100:291-296.
29. Bachmann E, Weber E. Biochemical mechanisms of oxfenicine cardiotoxicity. Pharmacology 1988;36:238-248.
30. Bielefeld DR, Vary TC, Neely JR. Inhibition of carnitine palmitoyl-CoA transferase activity and fatty acid oxidation by lactate and oxfenicine in cardiac muscle. J Mol Cell Cardiol 1985;17:619-625.
31. Welch MJ, Dence CS, Marshall DR, Kilbourn MR. Remote system for production of carbon-11-labeled palmitic acid. J Labeled Compds Radiopharm 1983;20:1087-1095.
32. DeGrado TR, Holden JE, Ng CK, et al. Quantitative analysis of myocardial kinetics of 15-p-[iodine-125] iodophenylpentadecanoic acid. J Nucl Med 1989;30:1211-1218.
33. Bergmann SR, Carlson E, Dannen E, Sobel BE. An improved assay with 4-(2-thiazolylazo)-resorcinol for free fatty acids in biological fluids. Clin Chim Acta 1980;104:53-63.
34. 11C-palmitate. Circulation 1981;64:689-699.
35. Grover-McKay M, Schelbert HR, Schwaiger M, et al. Identification of impaired metabolic reserve by atrial pacing in patients with significant coronary artery stenosis. Circulation 1986;74:281-292.
36. Bergmann SR, Herrero P, Hartman JJ, et al. Quantitative assessment of myocardial fatty acid metabolism in pediatric patients with inherited cardiomyopathy [Abstract]. Circulation 1995;92:1-444.
37. Fields LE, Daugherty A, Bergmann SR. Effect of fatty acid on performance and lipid content of hearts from diabetic rabbits. Am J Physiol:Heart Circ Physiol 1986;250: H1079-H1085.